Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Glycopeptide Antibiotics Global Market Report 2025
Request Sample Buy Now
Global Glycopeptide Antibiotics Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Glycopeptide Antibiotics Global Market Report 2025

By Drug (Vancomycin, Dalbavancin, Oritavancin, Other Drugs), By Route of Administration (Oral, Parenteral, Other Routes), By Indication (Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Glycopeptide Antibiotics Market Overview

• Glycopeptide Antibiotics market size has reached to $3.54 billion in 2024

• Expected to grow to $5.38 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%

• Growth Driver: The Surging Demand For Glycopeptide Antibiotics In The Face Of Rising Cancer And Infectious Disease Cases

• Market Trend: Leiden University's Breakthrough Discovery Of Enhanced Vancomycin Variants Marks A Milestone In Glycopeptide Innovation

• North America was the largest region in 2024.

What Is Covered Under Glycopeptide Antibiotics Market?

Glycopeptide antibiotics are a group of antibiotics having structures that either comprise a glycosylated cyclic or polycyclic non-ribosomal peptide, used to inhibit bacterial cell wall formation. They were first discovered from plant and soil bacteria.

The main drugs of glycopeptide antibiotics are vancomycin, dalbavancin, oritavancin, and others. Vancomycin belongs to a family of drugs known as glycopeptide antibiotics that eliminates microorganisms in the intestines and is used to treat colitis, which can develop after antibiotic therapy. These are administered through oral, parenteral, and other routes for the treatment of skin and structure infection, meningitis, clostridioides difficile infection, enterocolitis, and other indications by hospitals, specialty clinics, home care, and other end-users.

Glycopeptide Antibiotics Global Market Report 2025 Market Size and growth rate 2025 to 2029: Graph

What Is The Glycopeptide Antibiotics Market Size 2025 And Growth Rate?

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.54 billion in 2024 to $3.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.

What Is The Glycopeptide Antibiotics Market Growth Forecast?

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.38 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, R&D investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.

The forecast of 9.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers may strain U.S. infectious disease control by increasing costs of vancomycin and teicoplanin active pharmaceutical ingredients and intravenous formulations imported from Italy and Spain, exacerbating antibiotic resistance challenges and raising hospital-acquired infection treatment expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Glycopeptide Antibiotics Market Segmented?

1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications

4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsemgents:

1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution

2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection

3) By Oritavancin: Oritavancin IV (Intravenous) Formulation,Oritavancin Powder for Injection

4) By Other Drugs: Teicoplanin, Linezolid, Daptomycin, Other Glycopeptide and Lipoglycopeptide Antibiotics

4o

What Is Driving The Glycopeptide Antibiotics Market? The Surging Demand For Glycopeptide Antibiotics In The Face Of Rising Cancer And Infectious Disease Cases

The rising number of cancer and infectious disease cases is expected to propel the growth of the glycopeptide antibiotics market going forward. Cancer refers to a disease that occurs when certain body cells multiply beyond their limits and spread to other body regions, whereas, infectious diseases are disorders produced by organisms such as bacteria, viruses, fungus, or parasites. The glycopeptide antibiotics are used to treat a variety of infectious disorders caused by methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus bacteria that are resistant to beta-lactams and other antibiotics. In cancer patients, glycopeptide antibiotics are used to boost radiotherapy's antitumor effects by eliminating not only the targeted cancer cells but also distant cancer cells farther in the body. For instance, according to the American Cancer Society, a US-based non-profit health organization committed to cancer eradication, in 2022, the US had 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 fatalities each day. Therefore, the rising cancer and infectious disease cases will drive the growth of the glycopeptide antibiotics industry.

What Is Driving The Glycopeptide Antibiotics Market? Combatting Gram-Positive Threat The Surging Demand For Glycopeptide Antibiotics In Response To Rising Infection Rates

The increasing prevalence of gram-positive infections is expected to propel the growth of the glycopeptide antibiotic market in the coming years. Gram-positive infections are infections caused by gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and others. Glycopeptide antibiotics are effective against many gram-positive bacteria due to their unique mode of action, which targets bacterial cell wall formation. For instance, in November 2023, according to the English Surveillance Programme for Antimicrobial Utilization and Resistance (ESPAUR) Report 2022–2023 by the UK Health Security Agency, a UK-based government body in charge of public health and infectious disease protection throughout England, infections with Group A Streptococcus (iGAS) rose by 248% in 2022 compared to 2021. In comparison to pre-pandemic levels, there were 21% more iGAS cases recorded in 2022 than 3 years ago. Therefore, the increasing prevalence of gram-positive infections is driving the glycopeptide antibiotic industry.

Who Are The Major Players In The Global Glycopeptide Antibiotics Market?

Major companies operating in the glycopeptide antibiotics market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

What Are The Key Trends Of The Global Glycopeptide Antibiotics Market? Leiden University's Breakthrough Discovery Of Enhanced Vancomycin Variants Marks A Milestone In Glycopeptide Innovation

Product innovation is a key trend gaining popularity in the glycopeptide antibiotics market. Major companies operating in the glycopeptide antibiotics market are focused on developing innovative products to strengthen their position in the market. For instance, In October 2022, Leiden University, a Netherlands-based research university, discovered new variants of the antibiotic vancomycin. A group of molecules was attached to the structure of an existing vancomycin molecule to create the new variant antibiotic vancomycin. The new variant of vancomycin is up to a thousand times more active against gram-positive bacteria than the original vancomycin and has lower nephrotoxicity when compared to commercially utilized polymyxin antibiotics. This was created to solve the problem since vancomycin can only be effective against gram-positive strains and it cannot pass through the outer membrane (OM) of gram-negative bacteria.

What Are The Key Trends Of The Global Glycopeptide Antibiotics Market? Cumberland Pharmaceuticals And Tabuk Pharmaceutical's Strategic Partnership To Introduce Revolutionary Glycopeptide Antibiotics In The Middle East

Major companies operating in the glycopeptide antibiotics market are adopting a strategic partnership approach, aiming to bring life-saving revolutionary antibiotics to the Middle East. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in March 2022, Cumberland Pharmaceuticals Inc., a US-based specialty pharmaceutical company, announced a partnership with Tabuk Pharmaceutical Manufacturing Company. The news follows an agreement between the firms under which Tabuk would have exclusive trademark rights and promote the Vibativ (telavancin) injection for patients in Saudi Arabia, Jordan, and possibly additional Middle Eastern nations. Vibativ is a potentially life-saving medication for patients suffering from ventilator-associated pneumonia and hospital-acquired pneumonia caused by a variety of Gram-positive bacterial infections, including those that are difficult-to-treat and multidrug-resistant. Tabuk Pharmaceutical Manufacturing Company is a Saudi Arabia-based pharmaceutical company.

Need data on a specific region in this market?
Request Customisation

Glycopeptide Antibiotics Market Merger And Acquisition: Fairlong Capital LLC Acquired A Dosemerx Company.

In January 2023, Fairlong Capital LLC, a US-based investment company, acquired DoseMeRx for an undisclosed amount. Through this acquisition, Fairlong Capital aims to enhance its precision dosing capabilities and improve patient outcomes with advanced medication management solutions. This strategic move positions the company to leverage innovative technology for more effective healthcare delivery. DoseMeRx, a US-based Bayesian dosing platform, optimizes dosing for glycopeptide antibiotics, such as vancomycin, by personalizing treatment based on patient-specific factors

Regional Analysis For The Global Glycopeptide Antibiotics Market

North America was the largest region in the glycopeptide antibiotics market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glycopeptide Antibiotics Market?

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Glycopeptide Antibiotics Industry?

The glycopeptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Glycopeptide Antibiotics Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $3.78 billion
Revenue Forecast In 2034 $5.38 billion
Growth Rate CAGR of 9.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsemgents: 1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation,Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Linezolid, Daptomycin, Other Glycopeptide and Lipoglycopeptide Antibiotics 4o
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Glycopeptide Antibiotics Market Characteristics

3. Glycopeptide Antibiotics Market Trends And Strategies

4. Glycopeptide Antibiotics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Glycopeptide Antibiotics Growth Analysis And Strategic Analysis Framework

5.1. Global Glycopeptide Antibiotics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Glycopeptide Antibiotics Market Growth Rate Analysis

5.4. Global Glycopeptide Antibiotics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Glycopeptide Antibiotics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Glycopeptide Antibiotics Total Addressable Market (TAM)

6. Glycopeptide Antibiotics Market Segmentation

6.1. Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Vancomycin

Dalbavancin

Oritavancin

Other Drugs

6.2. Global Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Routes

6.3. Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Skin And Structure Infection

Meningitis

Clostridioides Difficile Infection

Enterocolitis

Other Indications

6.4. Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End-Users

6.5. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Vancomycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Vancomycin Injection

Vancomycin Oral Solution

Vancomycin Capsules

Vancomycin Powder for Solution

6.6. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Dalbavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Dalbavancin IV (Intravenous) Formulation

Dalbavancin Powder for Injection

6.7. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Oritavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oritavancin IV (Intravenous) Formulation

Oritavancin Powder for Injection

6.8. Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Teicoplanin

Linezolid

Daptomycin

Other Glycopeptide and Lipoglycopeptide Antibiotics

7. Glycopeptide Antibiotics Market Regional And Country Analysis

7.1. Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glycopeptide Antibiotics Market

8.1. Asia-Pacific Glycopeptide Antibiotics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glycopeptide Antibiotics Market

9.1. China Glycopeptide Antibiotics Market Overview

9.2. China Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glycopeptide Antibiotics Market

10.1. India Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glycopeptide Antibiotics Market

11.1. Japan Glycopeptide Antibiotics Market Overview

11.2. Japan Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glycopeptide Antibiotics Market

12.1. Australia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glycopeptide Antibiotics Market

13.1. Indonesia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glycopeptide Antibiotics Market

14.1. South Korea Glycopeptide Antibiotics Market Overview

14.2. South Korea Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glycopeptide Antibiotics Market

15.1. Western Europe Glycopeptide Antibiotics Market Overview

15.2. Western Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glycopeptide Antibiotics Market

16.1. UK Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glycopeptide Antibiotics Market

17.1. Germany Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glycopeptide Antibiotics Market

18.1. France Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glycopeptide Antibiotics Market

19.1. Italy Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glycopeptide Antibiotics Market

20.1. Spain Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glycopeptide Antibiotics Market

21.1. Eastern Europe Glycopeptide Antibiotics Market Overview

21.2. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glycopeptide Antibiotics Market

22.1. Russia Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glycopeptide Antibiotics Market

23.1. North America Glycopeptide Antibiotics Market Overview

23.2. North America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glycopeptide Antibiotics Market

24.1. USA Glycopeptide Antibiotics Market Overview

24.2. USA Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glycopeptide Antibiotics Market

25.1. Canada Glycopeptide Antibiotics Market Overview

25.2. Canada Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glycopeptide Antibiotics Market

26.1. South America Glycopeptide Antibiotics Market Overview

26.2. South America Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glycopeptide Antibiotics Market

27.1. Brazil Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glycopeptide Antibiotics Market

28.1. Middle East Glycopeptide Antibiotics Market Overview

28.2. Middle East Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glycopeptide Antibiotics Market

29.1. Africa Glycopeptide Antibiotics Market Overview

29.2. Africa Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glycopeptide Antibiotics Market Competitive Landscape And Company Profiles

30.1. Glycopeptide Antibiotics Market Competitive Landscape

30.2. Glycopeptide Antibiotics Market Company Profiles

30.2.1. ANI Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Hikma Pharmaceuticals Plc. Overview, Products and Services, Strategy and Financial Analysis

31. Glycopeptide Antibiotics Market Other Major And Innovative Companies

31.1. Aurobindo Pharma Limited

31.2. Abbvie Inc.

31.3. Cumberland Pharmaceuticals Inc.

31.4. Janssen Global

31.5. Bristol-Myers Squibb Company

31.6. Shenwei Pharmaceutical Hainan Co. Ltd.

31.7. Zhejiang Hisun Pharmaceutical Co. Ltd.

31.8. Alvogen

31.9. Bayer AG

31.10. Merck & Co. Inc.

31.11. Teva Pharmaceutical Industries Ltd.

31.12. Sanofi SA

31.13. GlaxoSmithKline plc

31.14. Johnson & Johnson

31.15. AstraZeneca

32. Global Glycopeptide Antibiotics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glycopeptide Antibiotics Market

34. Recent Developments In The Glycopeptide Antibiotics Market

35. Glycopeptide Antibiotics Market High Potential Countries, Segments and Strategies

35.1 Glycopeptide Antibiotics Market In 2029 - Countries Offering Most New Opportunities

35.2 Glycopeptide Antibiotics Market In 2029 - Segments Offering Most New Opportunities

35.3 Glycopeptide Antibiotics Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Vancomycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Dalbavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Oritavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: ANI Pharmaceuticals Inc. Financial Performance
  • Table 80: Fresenius SE & Co. KGaA Financial Performance
  • Table 81: Pfizer Inc. Financial Performance
  • Table 82: Novartis AG Financial Performance
  • Table 83: Hikma Pharmaceuticals Plc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Vancomycin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Dalbavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Oritavancin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Glycopeptide Antibiotics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Glycopeptide Antibiotics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: ANI Pharmaceuticals Inc. Financial Performance
  • Figure 80: Fresenius SE & Co. KGaA Financial Performance
  • Figure 81: Pfizer Inc. Financial Performance
  • Figure 82: Novartis AG Financial Performance
  • Figure 83: Hikma Pharmaceuticals Plc. Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Truck Mounted Crane Global Market Report 2025 – By Type (Articulating Cranes, Hydraulic Cranes, Telescopic Cranes, Other Types), By Drive (Electrical, Mechanical, Hydraulic), By Lifting Capacity (Below 15 Ton, 15 to 30 T...

View Report

Feed Mycotoxin Binders And Modifiers Global Market Report 2025 – By Type (Feed Mycotoxin Binders, Feed Mycotoxin Modifiers), By Source (Inorganic , Organic), By Livestock (Poultry, Swine, Ruminants, Aquatic Animals, Othe...

View Report

Luxury Electric Vehicles Global Market Report 2025 – By Type (Battery Electric Vehicle (BEV), Plug-In Hybrid Electric Vehicles (PHEVs), Fuel Cell Electric Vehicles (FCEVs), Hybrid), By Battery Type (Lead-Acid, Lithium-Io...

View Report

Sheep And Goat Pox Vaccines Global Market Report 2025 – By Type (Live Attenuated Vaccines, Inactivated Vaccines, Other Types), By Route Of Administration (Injectable, Intranasal), By Application (Sheep, Goat) – Impact of...

View Report

Pediatric And Neonatal Testing Kit Global Market Report 2025 – By Test Type (Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), Other Test Types), By Product (Assay Kits And Reagents, Instrumen...

View Report

Veterinary Antibiotics Global Market Report 2025 – By Product (Anti-parasitic, Anti-bacterial, Non-steroidal anti-inflammatory drug, Others), By End User (Farm Animals , Companion Animals), By Administration (Premixes, I...

View Report

Aluminum-Extruded Products Global Market Report 2025 - By Product Type (Mill Finished, Powder Coated, Anodized), By Alloy Type (1000 Series Aluminum, 2000 Series Aluminum Alloy, 3000 Series Aluminum Alloy, 5000 Series Al...

View Report

Bot Services Global Market Report 2025 – By Type (Text, Audio, Video), By Service (Framework, Platform), By Deployment (Social, Media, SMS, Website, Cloud), By End-User (BFSI, Retail, Healthcare, Media & Entertainment, T...

View Report

Frequently Asked Questions

Glycopeptide antibiotics are a group of antibiotics having structures that either comprise a glycosylated cyclic or polycyclic non-ribosomal peptide, used to inhibit bacterial cell wall formation. They were first discovered from plant and soil bacteria. For further insights on this market, request a sample here

The market major growth driver - The Surging Demand For Glycopeptide Antibiotics In The Face Of Rising Cancer And Infectious Disease Cases. For further insights on this market, request a sample here

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.54 billion in 2024 to $3.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases. The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to " $5.38 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, R&D investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies. For further insights on this market, request a sample here

The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation,Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Linezolid, Daptomycin, Other Glycopeptide and Lipoglycopeptide Antibiotics 4o For further insights on this market, request a sample here

North America was the largest region in the glycopeptide antibiotics market in 2024. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the glycopeptide antibiotics market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc. . For further insights on this market, request a sample here.

Major trends in this market include Leiden University's Breakthrough Discovery Of Enhanced Vancomycin Variants Marks A Milestone In Glycopeptide Innovation. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Glycopeptide Antibiotics Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon